Oppenheimer & Co. Inc. increased its position in shares of Celgene Corporation (NASDAQ:CELG) by 24.5% during the first quarter, Holdings Channel reports. The institutional investor owned 119,197 shares of the biopharmaceutical company’s stock after buying an additional 23,471 shares during the period. Oppenheimer & Co. Inc.’s holdings in Celgene Corporation were worth $14,832,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. DF Dent & Co. Inc. raised its position in Celgene Corporation by 1.1% in the first quarter. DF Dent & Co. Inc. now owns 894,174 shares of the biopharmaceutical company’s stock worth $111,262,000 after buying an additional 9,408 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in Celgene Corporation by 9.3% in the first quarter. Schwab Charles Investment Management Inc. now owns 2,896,278 shares of the biopharmaceutical company’s stock worth $360,384,000 after buying an additional 247,385 shares in the last quarter. Legal & General Group Plc raised its position in Celgene Corporation by 4.3% in the first quarter. Legal & General Group Plc now owns 3,587,623 shares of the biopharmaceutical company’s stock worth $446,406,000 after buying an additional 147,263 shares in the last quarter. Investec Asset Management PTY Ltd bought a new position in Celgene Corporation during the first quarter worth about $849,000. Finally, Investec Asset Management North America Inc. bought a new position in Celgene Corporation during the first quarter worth about $11,386,000. Institutional investors and hedge funds own 78.41% of the company’s stock.

Shares of Celgene Corporation (NASDAQ CELG) traded down 2.03% on Thursday, reaching $132.82. The company’s stock had a trading volume of 433,304 shares. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $139.00. The company has a market cap of $103.91 billion, a P/E ratio of 41.13 and a beta of 1.89. The company has a 50 day moving average price of $134.30 and a 200 day moving average price of $124.13.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter last year, the business posted $1.44 EPS. The company’s revenue for the quarter was up 18.7% on a year-over-year basis. On average, analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

WARNING: “Oppenheimer & Co. Inc. Has $14.83 Million Position in Celgene Corporation (NASDAQ:CELG)” was posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/oppenheimer-co-inc-has-14-83-million-position-in-celgene-corporation-nasdaqcelg/1470764.html.

A number of research analysts recently issued reports on the company. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $175.00 price objective on shares of Celgene Corporation in a research report on Wednesday. Cann restated a “buy” rating and set a $175.00 price objective on shares of Celgene Corporation in a research report on Tuesday, August 1st. Jefferies Group LLC restated a “buy” rating and set a $160.00 price objective on shares of Celgene Corporation in a research report on Monday, July 31st. Argus upgraded Celgene Corporation from a “hold” rating to a “buy” rating and boosted their price objective for the company from $96.93 to $160.00 in a research report on Monday, July 31st. Finally, Barclays PLC restated a “hold” rating and set a $135.00 price objective on shares of Celgene Corporation in a research report on Friday, July 28th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty-three have given a buy rating to the stock. Celgene Corporation has an average rating of “Buy” and a consensus price target of $147.06.

In other Celgene Corporation news, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total value of $1,008,900.00. Following the sale, the director now owns 76,301 shares of the company’s stock, valued at approximately $10,264,010.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rupert Vessey sold 4,785 shares of Celgene Corporation stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the sale, the insider now directly owns 4,004 shares in the company, valued at approximately $481,200.72. The disclosure for this sale can be found here. Insiders sold a total of 235,255 shares of company stock worth $31,377,042 in the last three months. Company insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.